Growth investing often centres on finding businesses that can expand earnings over long periods.
That does not always mean chasing early-stage companies. Some of the strongest growth stories on the ASX today are already established, with proven models and clear pathways to further expansion.
Here are three ASX growth shares that continue to stand out.
Pro Medicus Ltd (ASX: PME)
One company that continues to deliver strong growth is Pro Medicus.
This ASX growth share develops imaging software used by hospitals and healthcare providers. Its Visage platform is designed to handle large medical datasets with speed and efficiency.
The company’s recent performance highlights the strength of its model. It delivered revenue growth of 28.4% and profit growth of 29.7% during the first half of FY 2026, supported by new contract wins and expanding global adoption.
A key driver is its long-term contract structure, particularly in the United States. These agreements can run for several years and provide recurring, high-margin revenue.
With a growing sales pipeline and increasing adoption across different medical fields, Pro Medicus continues to build on its position in a specialised but expanding market.
Temple & Webster Group Ltd (ASX: TPW)
Another ASX growth share worth looking at is Temple & Webster Group. It offers exposure to a different type of growth opportunity.
Temple & Webster operates an online-only furniture and homewares platform. It benefits from the gradual shift toward e-commerce in categories that have traditionally been dominated by physical retail.
The company’s model is asset-light, allowing it to scale its product range without the costs associated with maintaining a large store network.
Growth in this segment can be uneven, influenced by housing activity and consumer spending. However, the long-term direction remains supported by increasing online penetration.
Temple & Webster’s focus on data, customer experience, and product range positions it to capture a larger share of the market as buying behaviour continues to evolve.
Xero Ltd (ASX: XRO)
Xero is another ASX growth share that has built strong momentum over time.
It provides cloud-based accounting software to small and medium-sized businesses. Xero’s platform sits at the centre of financial operations, making it an important part of day-to-day business activity.
The company’s long-term opportunity is tied to both subscriber growth and expanding functionality. It now serves millions of users globally and continues to invest in areas such as payments and artificial intelligence.
Its strategy reflects this. Xero is focused on becoming a broader financial platform, combining accounting with payments and insights. The addition of Melio is expected to accelerate its presence in the US and improve monetisation over time.
With a large addressable market and multiple growth drivers, Xero could be a share to hold for the long term.
The post 3 amazing ASX growth shares that continue to stand out appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you buy Pro Medicus shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Why Black Cat, Mirvac, Qantas, and Temple & Webster shares are falling today
- Why I’d invest $2,500 in Life360 and Pro Medicus shares today
- Are Xero shares a buy after rebounding 17% from three-year low
- Guess which ASX 200 stock is sinking 15% on CEO change
- Temple & Webster names Susie Sugden CEO as Mark Coulter becomes Executive Chair
Motley Fool contributor James Mickleboro has positions in Pro Medicus, Temple & Webster Group, and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Temple & Webster Group and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Pro Medicus and Temple & Webster Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.